Search Result

Results for "

pA2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (14) Adrenergic Receptor (8) Angiotensin Receptor (2) Bacterial (3) Biochemical Assay Reagents (1) Cholinesterase (ChE) (1) Dopamine Receptor (5) Endogenous Metabolite (2) Endothelin Receptor (4) Enterovirus (1) GCGR (2) GPR84 (1) Histamine Receptor (16) iGluR (1) Isotope-Labeled Compounds (6) JNK (1) Leukotriene Receptor (2) Liposome (1) mAChR (7) Natriuretic Peptide Receptor (NPR) (1) Neurokinin Receptor (4) Neuromedin U Receptor (NMUR) (2) Neuropeptide S Receptor (1) Opioid Receptor (4) Oxytocin Receptor (1) P2Y Receptor (2) Prostaglandin Receptor (2) PROTACs (1) RAR/RXR (1) Reference Standards (9) SARS-CoV (1) Small Interfering RNA (siRNA) (3) Toll-like Receptor (TLR) (1) Vasopressin Receptor (2)
By Research Areas:	Cancer (10) Cardiovascular Disease (16) Endocrinology (12) Infection (2) Inflammation/Immunology (16) Metabolic Disease (10) Neurological Disease (33)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Phospholipids (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0693

Ranitidine 3 Publications Verification	Histamine Receptor	Metabolic Disease Cancer
Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with *pA₂* values of 7.2 and 6.95, respectively. Ranitidine inhibits breast tumor development and spread in mice ^[2].

HY-10349

WAY-100635 Maximum Cited Publications 12 Publications Verification	5-HT Receptor Dopamine Receptor	Neurological Disease
WAY-100635 is a potent and selective 5-HT_1A Receptor antagonist with a pIC₅₀ of 8.87, an apparent pA₂ of 9.71. WAY-100635 is a potent and selective 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist with an IC₅₀ value of 0.91 nM and K_i value of 0.39 nM. WAY-100635 has pIC₅₀ values for 5-HT1A and α1-adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 is also a potent dopamine D₄ receptor agonist ^[2] .

HY-B0281A

Ranitidine hydrochloride 3 Publications Verification	Histamine Receptor	Metabolic Disease Cancer
Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine hydrochloride antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with *pA₂* values of 7.2 and 6.95, respectively. Ranitidine hydrochloride inhibits breast tumor development and spread in mice ^[2].

HY-15895

Aprocitentan 3 Publications Verification ACT-132577	Endothelin Receptor	Cardiovascular Disease Endocrinology
Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual ETA/ETB antagonist with IC₅₀s of 3.4 nM and 987 nM, and *pA₂* valus of 6.7 and 5.5, respectively. Aprocitentan is an antihypertensive agent .

HY-76569

Desfesoterodine 1 Publications Verification PNU-200577; 5-Hydroxymethyl Tolterodine	mAChR	Neurological Disease Cancer
Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a K_B and a *pA₂* of 0.84 nM and 9.14, respectively . Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053) ^[2] . Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats .

HY-107647

(S)-(+)-Dimethindene maleate 1 Publications Verification	mAChR Histamine Receptor	Inflammation/Immunology
(S)-(+)-Dimethindene maleate, an enantiomer, is a potent M₂-selective muscarinic receptor antagonist (pA₂ = 7.86/7.74; pK_i = 7.78). (S)-(+)-Dimethindene maleate shows lower affinities for the muscarinic M₁ (pA₂ = 6.83/6.36; pK_i = 7.08), the M₃ (pA₂ = 6.92/6.96; pK_i = 6.70) and the M₄ receptors (pK_i = 7.00), respectively. (S)-(+)-Dimethindene maleate also is a histamine H₁ receptor antagonist (pA₂ = 7.48) .

HY-15010

L-371,257 1 Publications Verification	Oxytocin Receptor Vasopressin Receptor	Cardiovascular Disease Endocrinology
L-371,257 is an orally bioavailable, non-blood-brain barrier penetrant, selective and competitive antagonist of oxytocin receptor (pA2=8.4) with high affinity at both the oxytocin receptor (K_i=19 nM) and vasopressin V1a receptor (K_i=3.7 nM) ^[2].

HY-108626

ML154 NCGC84	Neuropeptide S Receptor	Neurological Disease
ML154 (NCGC84) is a selective, brain-penetrant and non-peptide neuropeptide S receptor (NPSR) antagonist with a *pA₂* of 9.98. ML154 potently inhibits NPS-stimulated cellular calcium, cAMP, and ERK phosphorylation responses with IC₅₀ values of 36.5 nM, 22.1 nM, and 9.3 nM, respectively ^[2].

HY-15895S

Aprocitentan-d4 ACT-132577-d₄	Isotope-Labeled Compounds Endothelin Receptor	Cardiovascular Disease Endocrinology
Aprocitentan-d₄ is a deuterium labeled Aprocitentan. Aprocitentan is a major and pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual ETA/ETB antagonist with IC50s of 3.4 nM and 987 nM, and pA2 valus of 6.7 and 5.5, respectively. Aprocitentan is an antihypertensive agent .

HY-101189

JNJ-39758979	Histamine Receptor	Neurological Disease Endocrinology
JNJ-39758979, a chemical probe, is a selective, orally active, and high-affinity histamine H₄ receptor antagonist with K_is of 12.5, 5.3, and 25 nM for human, mouse, and monkey histamine H₄ receptor, respectively. JNJ-39758979 functionally antagonizes histamine-induced cAMP inhibition with a pA2 of 7.9 in transfected cells. JNJ-39758979 shows good anti-inflammatory and antipruritic activity ^[2].

HY-101336

RS 17053 hydrochloride RS-17053	Adrenergic Receptor	Metabolic Disease Endocrinology
RS 17053 hydrochloride is a potent and selective α1_A adrenoceptor antagonist, with a pK_i value of 9.1 in native cell membrane and a *pA₂* value of 9.8 in functional assays.

HY-17351

Tezosentan RO 610612	Endothelin Receptor	Cardiovascular Disease Neurological Disease Endocrinology Cancer
Tezosentan (RO 610612) is an endothelin (ET) receptor antagonist, with *pA₂s* of 9.5, 7.7 for ET_A and ET_B receptors, respectively.

HY-101232

Tiotidine 2 Publications Verification ICI 125211	Histamine Receptor	Cardiovascular Disease
Tiotidine (ICI 125211) is a potent and selective antagonist of histamine H2-receptor (pA₂=7.3-7.8 for guinea-pig right atrium). Tiotidine has low affinity for both the H1 and the H3 receptors ^[2].

HY-P2026

A 71915	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
A 71915 is a highly potent and competitive natriuretic peptide receptor A (ANP, NPRA) antagonist (pK_i= 9.18). A 71915 displaces [ ¹²⁵I]ANP dose dependently, with a K_i of 0.65 nM. A71915( pA₂= 9.48) against rat ANP-induced cGMP production in NB-OK-1 cells .

HY-101308A

MRS2179 tetrasodium hydrate 2 Publications Verification	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium hydrate is a competitive *P2Y1* receptor antagonist, with a K_b of 102 nM and a *pA₂* of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors ^[2]. MRS2179 tetrasodium hydrate inhibits platelet aggregation .

HY-108562

SC-51322	Prostaglandin Receptor	Neurological Disease
SC-51322 is a potent and selective antagonist of *prostaglandin E2 (PGE₂)* receptor (EP ₁), with a pA₂** of 8.1. SC-51322 has the pain-relieving effect .

HY-P1143A

[Des-His1,Glu9]-Glucagon amide TFA	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the glucagon receptor, with a *pA₂* of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .

HY-103428

LE 300 2 Publications Verification	Dopamine Receptor 5-HT Receptor	Neurological Disease
LE 300 is a potent and selective dopamine D1-like receptor antagonist with K_is of 1.9 nM and 7.5 nM in CHO cell membranes expressing human dopamine D1 and D5 receptors, respectively. LE 300 is an antagonist of the 5-HT_2A receptor with a pA2 of 8.32 in a rat tail artery assay ^[2].

HY-P1143

[Des-His1,Glu9]-Glucagon amide	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the glucagon receptor, with a *pA₂* of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .

HY-151413

MEN 10207 1 Publications Verification	Neurokinin Receptor	Neurological Disease
MEN 10207 is a selective NK-2 tachykinin receptor (Neurokinin Receptor) antagonist. MEN 10207 has pA2 values of 5.2, 7.9 and 4.9 in three monoreceptor in vitro assays for NK-1, NK-2 and NK-3 tachykinin receptors, respectively.

HY-P10473A

CPN-351 TFA	Neuromedin U Receptor (NMUR)	Inflammation/Immunology
CPN-351 TFA (compound 9a), a pentapeptide, is a selective antagonist of human NMUR1 with a *pA₂* of 7.35. The antagonistic effect of CPN-351 TFA on human NMUR1 is 10 times higher than that on NMUR2. CPN-351 TFA can be used in the study of inflammation . X

HY-103135

SB 206553 hydrochloride	5-HT Receptor	Neurological Disease
SB 206553 hydrochloride is a high affinity, selective and orally active 5-HT_2B / 5-HT_2C receptor antagonist (rat 5-HT_2B pA2 = 8.89, human 5-HT_2C pKi = 7.92) . SB 206553 possesses anxiolytic-like properties ^[2].

HY-B0693A

Ranitidine bismuth citrate	Histamine Receptor SARS-CoV Bacterial	Infection Metabolic Disease Cancer
Ranitidine bismuth citrate is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine bismuth citrate antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with *pA₂* values of 7.2 and 6.95, respectively. Ranitidine bismuth citrate has selectivity for *SARS-CoV-2*-infected cells. Ranitidine bismuth citrate also has anti-Helicobacter pylori infection. Ranitidine bismuth citrate inhibits breast tumor development and spread in mice ^[2] .

HY-P11091

PA2-GNU7	Bacterial	Infection
PA2-GNU7 is an antimicrobial peptide (AMP). PA2-GNU7 exhibits potent antimicrobial activity with minimal inhibitory concentration (MIC) against P. aeruginosa, E. coli, S. typhimurium, S. aureus, and C. albicans are 2 μM, 1 μM, 2 μM, 2 μM, and 8 μM, respectively. PA2-GNU7 rapidly and selectively kills Pseudomonas aeruginosa without affecting other commensal bacteria. PA2-GNU7 significantly improves survival of mice infected with P. aeruginosa. PA2-GNU7 can be used for the research and development of therapeutic agents against MDR Pseudomonas aeruginosa infections .

HY-144377

RXR antagonist 1	RAR/RXR	Neurological Disease Metabolic Disease Cancer
RXR antagonist 1 (compound 6a) is a retinoid X receptor (RXR) modulator. RXR antagonist 1 shows potent RXR-antagonistic activity, with a pA₂ of 8.06. RXR antagonist 1 can be used for type 2 diabetes research .

HY-P10473

CPN-351	Neuromedin U Receptor (NMUR)	Inflammation/Immunology
CPN-351 (compound 9a), a pentapeptide, is a selective antagonist of human NMUR1 with a *pA₂* of 7.35. The antagonistic effect of CPN-351 on human NMUR1 is 10 times higher than that on NMUR2. CPN-351 can be used in the study of inflammation .

HY-19432

UBP-282	iGluR	Neurological Disease
UBP-282 is a potent, selective and competitive AMPA and kainate receptor antagonist. UBP-282 inhibits the fast component of the dorsal root-evoked ventral root potential (fDR-VRP) with an IC₅₀ value of 10.3 μM. UBP-282 antagonizes kainate-induced depolarisations of dorsal roots with a *pA₂* value of 4.96 ^[2].

HY-14782

Adoprazine SLV313	5-HT Receptor Dopamine Receptor	Neurological Disease
Adoprazine (SLV313) is a full 5-HT_1A receptor agonist with a pEC₅₀ of 9 at cloned h5-HT_1A receptors. Adoprazine (SLV313) is a full D₂ and D₃ receptor antagonist with *pA₂s* of 9.3 and 8.9 at hD₂ and hD₃ receptors, respectively. Adoprazine (SLV313) has the characteristics of atypical antipsychotics .

HY-P3850

(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B	Neurokinin Receptor	Neurological Disease
(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B is a competitive antagonist of Neurokinin B (Neurokinin Receptor) with a pA2 of 5.5. (D-Pro2,D-Trp6,8,Nle10)-Neurokinin B shows no influence on Substance P or Neurokinin A .

HY-16979

TRK-851	Opioid Receptor	Neurological Disease
RK-851 is a highly selective and orally active δ-opioid receptor antagonist, with a negative logarithm of the antagonist concentration (pA₂) of 8.84. TRK-851 exhibits the selectivity for the δ receptor of more than 100 times higher than that for the μ or κ receptors. TRK-851 exhibits a potent antitussive effect in a rat model of capsaicin-induced cough. TRK-851 can be used for research on antitussive effects .

HY-101308

MRS2179 tetrasodium	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium is a competitive *P2Y1* receptor antagonist, with a K_b of 102 nM and a *pA₂* of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors ^[2]. MRS2179 tetrasodium inhibits platelet aggregation .

HY-P1320

[Nphe1]Nociceptin(1-13)NH2	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .

HY-76569R

Desfesoterodine (Standard) PNU-200577 (Standard); 5-Hydroxymethyl Tolterodine (Standard)	Reference Standards mAChR	Neurological Disease
Desfesoterodine (Standard) is the analytical standard of Desfesoterodine. This product is intended for research and analytical applications. Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a K_B and a *pA₂* of 0.84 nM and 9.14, respectively . Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053) ^[2] . Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats .

HY-170601

PROTAC JNK1-targeted-1	PROTACs JNK	Cancer
PROTAC JNK1-targeted-1 (PA2) is a JNK1 PROTAC degrader, with a DC₅₀ of 10 nM. PROTAC JNK1-targeted-1 (PA2) decreases the level of Fibronectin protein. PROTAC JNK1-targeted-1 can be used for the research of pulmonary fibrosis . (Pink: JNK1 inhibitor (HY-170602); Black: linker (HY-40178); Blue: CRBN Ligand (HY-41547))

HY-105483

MDL 43291	Leukotriene Receptor	Inflammation/Immunology
MDL 43291 is a competitive leukotriene (LT) receptor antagonist. MDL 43291 antagonize LTD4 and LTE4 with *pA2* of 6.7. MDL 43291 does not antagonize histamine, carbachol or substance P. MDL 43291 can be used for the researches of inflammation and immunology, such as asthma .

HY-15895R

Aprocitentan (Standard) ACT-132577 (Standard)	Reference Standards Endothelin Receptor	Cardiovascular Disease Endocrinology
Aprocitentan (Standard) is the analytical standard of Aprocitentan. This product is intended for research and analytical applications. Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of Macitentan. Aprocitentan is dual ETA/ETB antagonist with IC50s of 3.4 nM and 987 nM, and pA2 valus of 6.7 and 5.5, respectively .

HY-P5006

(d(CH2)51,Tyr(Me)2,Dab5,Arg8)-Vasopressin d(CH2)5[Tyr(Me)2, Dab5]AVP	Vasopressin Receptor	Cardiovascular Disease
(d(CH2)51,Tyr(Me)2,Dab5,Arg8)-Vasopressin (d(CH2)5[Tyr(Me)2, Dab5]AVP) is a specific antagonist of vasopressin V_1a receptor, with a pA₂ of 6.71 .

HY-10382

EXP-6803	Angiotensin Receptor	Cardiovascular Disease
EXP-6803 is a specific nonpeptide angiotensin II receptor antagonist with antihypertensive activity. EXP-6803 inhibits the contractile response to angiotensin II with a pA₂ value of 7.20. EXP-6803 effectively blocks responses to angiotensin I and II while not affecting responses to bradykinin or acetylcholine in guinea pig ileum. EXP-6803 can be used for hypertension research .

HY-P11442

*Lytx-Pa2a* Lycotoxin-pA2a; TBIU041425	Bacterial Toll-like Receptor (TLR)	Inflammation/Immunology
Lytx-Pa2a (Lycotoxin-Pa2a) is a peptide inhibitor against bacterial membranes and TLR4 receptor. Lytx-Pa2a exerts antimicrobial effects via non-competitive disruption of outer/cytoplasmic membranes and suppression of LPS-induced TLR4/NF-κB signaling. Lytx-Pa2a is promising for research of bacterial infection and inflammation-related disease (e.g., sepsis) .

HY-100152

Beperidium iodide SX 810	mAChR	Inflammation/Immunology
Beperidium iodide shows a competitive antagonistic effect against acetylcholine receptor with a *pA2* of 7.93.

HY-121603

Bornaprine	Cholinesterase (ChE)	Neurological Disease
Bornaprine is an anticholinergic agent that can be used in the study of parkinsonism. Bornaprine shows a pA2 value of 7.27 .

HY-P1017

MDL 29913	Neurokinin Receptor	Cardiovascular Disease Neurological Disease
MDL 29913, a cyclic pseudopeptide, is a competitive *NK₂* tachykinin receptor selective antagonist, with a pA₂ of 8.66 .

HY-76569S1

(R)-Hydroxytolterodine-d14 PNU-200577-d₁₄; 5-Hydroxymethyl Tolterodine-d₁₄	mAChR Isotope-Labeled Compounds	Neurological Disease
(R)-Hydroxytolterodine-d₁₄ is deuterated labeled Desfesoterodine (HY-76569). Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a K_B and a *pA₂* of 0.84 nM and 9.14, respectively . Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053) ^[2] . Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats .

HY-139045

2,4-DMA hydrochloride	5-HT Receptor	Neurological Disease
2,4-DMA hydrochloride is an amphetamine and is a serotonin 5-HT2 receptor agonist with an apparent *PA₂* value of 5.6 .

HY-U00355

YM158 free base YM-57158	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
YM158 free base is a potent and selective LTD₄ and TXA₂ receptor antagonist with *pA₂* values of about 8.87 and 8.81, respectively.

HY-W713312

2,6-DMA hydrochloride	5-HT Receptor	Neurological Disease
2,6-DMA hydrochloride is classified as an amphetamine. 2,6-DMA hydrochloride is a serotonin 5-HT2 receptor agonist with an apparent pA2 value of 5.09.

HY-19136

WAY-100289	5-HT Receptor	Neurological Disease
WAY-100289 is an orally active antagonist for 5-HT3 receptor, that exhibits high affinity to the isolated rat vagus nerves with pA₂ of 8.9. WAY-100289 inhibits the Bezold-Jarisch reflex in anesthetized and awake rats .

HY-14757

Trelanserin SL-650472	5-HT Receptor	Neurological Disease
Trelanserin (SL-650472) is a 5-HT receptor antagonist and also an effective in vitro smooth muscle contraction antagonist, competing against the contractions induced by sumatriptan (HY-B0121B) with a pA2 of 8.17±0.36 .

HY-119262

ABT-866	Adrenergic Receptor	Cardiovascular Disease Endocrinology
ABT-866 is an α_1A-adrenoceptor agonist and an antagonist at the α_1B- and α_1D-adrenoceptor subtypes. ABT-866 has an EC₅₀ of 0.60 μM for the α_1A in the rabbit urethra. ABT-866 has a *pA₂* value of 5.4 for the α_1B in the rat spleen. ABT-866 has a *pA₂* value of 6.2 for the α_1D in the rat aorta. ABT-866 exhibits good urethral selectivity and lower cardiovascular side effects in stress urinary incontinence models. ABT-866 can be used for the research of diseases such as stress urinary incontinence ^[2].

HY-170474

2-Methyl-N,N-dimethyltryptamine 2,N,N-TMT; 2-Me-DMT	5-HT Receptor	Neurological Disease
2-Methyl-N,N-dimethyltryptamine (2,N,N-TMT, compound 15) has binding affinity for serotonin (5-HT) receptor, with the *pA2* of 6.04. 2-Methyl-N,N-dimethyltryptamine plays an important role in neurological disease research .

Cat. No.	Product Name	Target	Research Area

HY-P2026

A 71915	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
A 71915 is a highly potent and competitive natriuretic peptide receptor A (ANP, NPRA) antagonist (pK_i= 9.18). A 71915 displaces [ ¹²⁵I]ANP dose dependently, with a K_i of 0.65 nM. A71915( pA₂= 9.48) against rat ANP-induced cGMP production in NB-OK-1 cells .

HY-P1143A

[Des-His1,Glu9]-Glucagon amide TFA	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the glucagon receptor, with a *pA₂* of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .

HY-P1143

[Des-His1,Glu9]-Glucagon amide	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the glucagon receptor, with a *pA₂* of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .

HY-151413

MEN 10207 1 Publications Verification	Neurokinin Receptor	Neurological Disease
MEN 10207 is a selective NK-2 tachykinin receptor (Neurokinin Receptor) antagonist. MEN 10207 has pA2 values of 5.2, 7.9 and 4.9 in three monoreceptor in vitro assays for NK-1, NK-2 and NK-3 tachykinin receptors, respectively.

HY-P10473A

CPN-351 TFA	Neuromedin U Receptor (NMUR)	Inflammation/Immunology
CPN-351 TFA (compound 9a), a pentapeptide, is a selective antagonist of human NMUR1 with a *pA₂* of 7.35. The antagonistic effect of CPN-351 TFA on human NMUR1 is 10 times higher than that on NMUR2. CPN-351 TFA can be used in the study of inflammation . X

HY-P11091

PA2-GNU7	Bacterial	Infection
PA2-GNU7 is an antimicrobial peptide (AMP). PA2-GNU7 exhibits potent antimicrobial activity with minimal inhibitory concentration (MIC) against P. aeruginosa, E. coli, S. typhimurium, S. aureus, and C. albicans are 2 μM, 1 μM, 2 μM, 2 μM, and 8 μM, respectively. PA2-GNU7 rapidly and selectively kills Pseudomonas aeruginosa without affecting other commensal bacteria. PA2-GNU7 significantly improves survival of mice infected with P. aeruginosa. PA2-GNU7 can be used for the research and development of therapeutic agents against MDR Pseudomonas aeruginosa infections .

HY-P10473

CPN-351	Neuromedin U Receptor (NMUR)	Inflammation/Immunology
CPN-351 (compound 9a), a pentapeptide, is a selective antagonist of human NMUR1 with a *pA₂* of 7.35. The antagonistic effect of CPN-351 on human NMUR1 is 10 times higher than that on NMUR2. CPN-351 can be used in the study of inflammation .

HY-P3850

(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B	Neurokinin Receptor	Neurological Disease
(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B is a competitive antagonist of Neurokinin B (Neurokinin Receptor) with a pA2 of 5.5. (D-Pro2,D-Trp6,8,Nle10)-Neurokinin B shows no influence on Substance P or Neurokinin A .

HY-P1320

[Nphe1]Nociceptin(1-13)NH2	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .

HY-P5006

(d(CH2)51,Tyr(Me)2,Dab5,Arg8)-Vasopressin d(CH2)5[Tyr(Me)2, Dab5]AVP	Vasopressin Receptor	Cardiovascular Disease
(d(CH2)51,Tyr(Me)2,Dab5,Arg8)-Vasopressin (d(CH2)5[Tyr(Me)2, Dab5]AVP) is a specific antagonist of vasopressin V_1a receptor, with a pA₂ of 6.71 .

HY-P11442

*Lytx-Pa2a* Lycotoxin-pA2a; TBIU041425	Bacterial Toll-like Receptor (TLR)	Inflammation/Immunology
Lytx-Pa2a (Lycotoxin-Pa2a) is a peptide inhibitor against bacterial membranes and TLR4 receptor. Lytx-Pa2a exerts antimicrobial effects via non-competitive disruption of outer/cytoplasmic membranes and suppression of LPS-induced TLR4/NF-κB signaling. Lytx-Pa2a is promising for research of bacterial infection and inflammation-related disease (e.g., sepsis) .

HY-P1017

MDL 29913	Neurokinin Receptor	Cardiovascular Disease Neurological Disease
MDL 29913, a cyclic pseudopeptide, is a competitive *NK₂* tachykinin receptor selective antagonist, with a pA₂ of 8.66 .

HY-P1320A

[Nphe1]Nociceptin(1-13)NH2 TFA	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2?binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .

HY-103294

R892	Endogenous Metabolite	Others
R892 is a selective and efficient bradyK_inin B1 receptor antagonist with significant antagonistic activity. The pA2 values of R892 in human and rabbit B1 receptors are 8.8 and 8.6 respectively, indicating its strong anti-activity at these receptors. R892 exhibits selectivity with ID50 values of 2.8 nM and >600 nM for B1 and B2 receptors, respectively, and has no endogenous agonist activity. R892 is resistant to aminopeptidase and kininase II (ACE) degradation and exhibits metabolic stability .

Species:	Human (3) Mouse (1)
Tag:	His (2) Fc (2)
Source:	HEK293 (3) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71219

	Podoplanin Protein, Mouse (HEK293, Fc) Podoplanin; Aggrus; Glycoprotein 38; Gp38; pA2.26 antigen; T1-alpha; T1A	Mouse	HEK293
	Podoplanin plays a crucial role in cell migration and adhesion by interacting with various partners. It promotes platelet activation and aggregation by binding to CLEC1B, but attenuates platelet aggregation and lung metastasis by interacting with CD9. Podoplanin Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Podoplanin protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P75726

	EBP1 Protein, Human (His) Proliferation-associated protein 2G4; hG4-1; ErbB3-binding protein 1; pA2G4	Human	E. coli
	EBP1 protein participates in the signal transduction pathway regulated by ERBB3 and is related to growth regulation. As an androgen receptor (AR) corepressor, it is regulated by the ERBB3 ligand neregulin-1/heregulin (HRG). EBP1 Protein, Human (His) is the recombinant human-derived EBP1 protein, expressed by E. coli , with N-His labeled tag.

HY-P71218

	Podoplanin Protein, Human (HEK293, His) Podoplanin; Aggrus; Glycoprotein 36; Gp36; pA2.26 Antigen; T1-Alpha; T1A; PDPN; GP36	Human	HEK293
	The Podoplanin protein is a multifaceted regulator that affects cell migration and adhesion through multiple interactions. In hemo-lymphatic dissociation, Podoplanin binds to CLEC1B, triggering platelet activation that is counteracted by the CD9 interaction. Podoplanin Protein, Human (HEK293, His) is the recombinant human-derived Podoplanin protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P704849

	Podoplanin Protein, Human (HEK293, Fc) Podoplanin; Aggrus; Glycoprotein 36; Gp36; pA2.26 Antigen; T1-Alpha; T1A; PDPN; GP36	Human	HEK293

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15895S

Aprocitentan-d4
Aprocitentan-d₄ is a deuterium labeled Aprocitentan. Aprocitentan is a major and pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual ETA/ETB antagonist with IC50s of 3.4 nM and 987 nM, and pA2 valus of 6.7 and 5.5, respectively. Aprocitentan is an antihypertensive agent .

HY-76569S1

(R)-Hydroxytolterodine-d14

(R)-Hydroxytolterodine-d₁₄ is deuterated labeled Desfesoterodine (HY-76569). Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a K_B and a pA₂ of 0.84 nM and 9.14, respectively . Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053) ^[2] . Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats .

HY-100634S

4-Hydroxypropranolol-d7 hydrochloride

4-Hydroxypropranolol-d₇ (hydrochloride) is a deuterium labeled 4-Hydroxypropranolol hydrochloride. 4-Hydroxypropranolol hydrochlorid is an active metabolite of Propranolol, with potency comparable to Propranolol. 4-Hydroxypropranolol hydrochlorid inhibits β1- and β2-adrenergic receptors with pA2 values of 8.24 and 8.26, respectively. 4-Hydroxypropranolol hydrochlorid has intrinsic sympathomimetic activity, membrane stabilizing activity and potent antioxidant properties ^[2] .

HY-B0281AS

Ranitidine-d6 hydrochloride

Ranitidine-d₆ hydrochloride is the deuterium labeled Ranitidine hydrochloride (HY-B0281A) . Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine hydrochloride antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA₂ values of 7.2 and 6.95, respectively. Ranitidine hydrochloride inhibits breast tumor development and spread in mice ^[2] .

HY-100634SA

4-Hydroxypropranolol-d7

4-Hydroxypropranolol-d₇ is the deuterium labeled 4-Hydroxypropranolol hydrochloride. 4-Hydroxypropranolol hydrochlorid is an active metabolite of Propranolol. 4-Hydroxypropranolol hydrochlorid is of comparable potency to Propranolol. 4-Hydroxypropranolol hydrochlorid inhibits β1- and β2-adrenergic receptors with pA2 values of 8.24 and 8.26, respectively. 4-Hydroxypropranolol hydrochlorid has intrinsic sympathomimetic activity, membrane stabilizing activity and potent antioxidant properties ^[2] .

HY-B0693S

Ranitidine-d6

Ranitidine-d₆ is the deuterium labeled Ranitidine (HY-B0693). Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA2 values of 7.2 and 6.95, respectively. Ranitidine inhibits breast tumor development and spread in mice ^[2].

Host:	Mouse (2) Rabbit (2)
Reactivity:	Human (4) Rat (2) Mouse (2)
Application:	IHC-P (4) ICC/IF (3) IP (2) WB (3) FC (1) ELISA (3)
Isotype:	IgG (2) IgG1 (2)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (4) Recombinant (1)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85910

	Podoplanin Antibody (YA5602) Aggrus; Glycoprotein 36; Gp36; pA2.26 antigen; T1-alpha; T1A	IHC-P, WB, ICC/IF, ELISA	Human
	Podoplanin Antibody (YA5602) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Podoplanin.

HY-P86249

	Podoplanin Antibody (YA5941) Podoplanin; Aggrus; Glycoprotein 36; Gp36; pA2.26 antigen; T1-alpha; T1A;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Podoplanin Antibody (YA5941) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Podoplanin.

HY-P85979

	Podoplanin Antibody (YA5671) Podoplanin; Aggrus; Glycoprotein 36; Gp36; pA2.26 antigen; T1-alpha; T1A;	IHC-P, ELISA	Human
	Podoplanin Antibody (YA5671) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Podoplanin.

HY-P82764

	EBP1 Antibody (YA2509) pA2G4; EBP1; Proliferation-associated protein 2G4; Cell cycle protein p38-2G4 homolog; hG4-1; ErbB3-binding protein 1	WB, IHC-P, ICC/IF, FC, IP	Human, Mouse, Rat
	EBP1 Antibody (YA2509) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EBP1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: